Newsletter - Banner
Respiratory viral infections in children: the long and the short of it
First presenter: Jesse Papenburg, MD, FRCPC
Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Faculty of Medicine, McGill University
Dr. Papenburg practices Pediatric Infectious Diseases and Medical Microbiology at the Montreal Children’s Hospital. His research program is supported by the Fonds de recherche Québec santé and studies the epidemiology, surveillance and diagnosis of severe viral respiratory infections in children.
Dr. Papenburg will be speaking about management and prevention of acute viral respiratory infections in children using provincial and local data to inform clinical practice and health policies.
Elimination of HIV and HCV in Vulnerable Populations
Second presenter: Marina Klein, MD, M.Sc., FRCPC
Professor, Department of Medicine, Division of Infectious Diseases
Faculty of Medicine, McGill University
New, highly effective therapies that directly target HCV (DAAs) will completely alter the landscape for HCV infected patients. But we are faced with a fundamental paradox. DAAs are the most expensive anti-infectives ever to be developed and HCV disproportionately affects the poorest and most disenfranchised populations in Canada and globally.
Over the last 15 years, I have built a national clinical research network funded by a CIHR Foundation grant, the Canadian Coinfection Cohort (www.cocostudy.ca) which has followed over 1800 HIV-HCV coinfected participants. Our high quality observational data, methods and linked biobank has supported a broad range of Canadian and international research efforts and trained many young investigators. The introduction of DAAs into this well characterized prospective cohort provides a unique opportunity to evaluate their full impact on coinfected Canadians and inform the wider response to the HCV epidemic by demonstrating how to increase access to and optimally use these new therapies.
This presentation will discuss how a collaborative research agenda, inclusive of communities affected, can serve as a model for evaluating health interventions in vulnerable populations. I will illustrate how research results can be used to engage policy makers to bring about equitable access to HCV treatment, maximize successful outcomes and reduce health and economic burdens in vulnerable and marginalized populations.
When: Wednesday, October 24, 2018 at noon
Where: 5252 boul de Maisonneuve West, 3rd Floor (3B kitchen)
Information: CORE 514-934-1934 ext. 48292 or Core.email@example.com
The presentation will be delivered in English.